Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00584935 · ClinicalTrials.gov registry record · Phase 1
Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid
A Phase 1 study of Ocular Cicatricial Pemphigoid, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
- 1
- Study location
NCT00584935: Completed Phase 1 study of Ocular Cicatricial Pemphigoid, sponsored by University of Alabama at Birmingham.
NCT00584935 is a Phase 1 study of Ocular Cicatricial Pemphigoid that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00584935, a Phase 1 study of Ocular Cicatricial Pemphigoid, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
- 1
- Study location
Study Summary
Cicatricial pemphigoid is an autoimmune blistering disease which affects the skin, mucous membranes, and, in a small subset of patients, the eye. Progressive ocular disease can lead to irreversible damage and blindness. Conventional treatments include systemic steroids, dapsone, and immunosuppressive agents. These treatments, however, are not successful with all patients. Rituximab has been very effective in the treatment of other autoimmune disorders, and has recently been shown to be effective for autoimmune blistering pemphigus. We propose that it will also be effective in the treatment of cicatricial pemphigoid.
Primary Outcome
Stages Characteristics I Subconjunctival scarring and fibrosis II Fornix foreshortening (a-d describes % loss of inferior fornix depth) 1. 0-25% 2. 25-50% 3. 50-75% 4. 75-100% III Presence of symblepharon and number (n) (a-d describes % of horizontal involvement by symblepharons and n is the number of symblepharons countable) a. 0-25% b. 25-50% c. 50-75% d. 75-100% IV Ankyloblepharon, frozen globe
Conditions Studied
Interventions
- DRUG Rituximab
Study Locations (1)
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2006-01 |
| Est. Completion | 2010-05 |
| Phase | Phase 1 |
What the finished NCT00584935 record still lists
NCT00584935 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Ocular Cicatricial Pemphigoid appearing as the primary indexed condition, and to 1 intervention - of which Rituximab is the first listed.
NCT00584935 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT00584935 about?
NCT00584935 is a clinical study titled "Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid". Cicatricial pemphigoid is an autoimmune blistering disease which affects the skin, mucous membranes, and, in a small subset of patients, the eye. Progressive ocular disease can lead to irreversible damage and blindness. Conventional treatments include systemic steroids, dapsone, and immunosuppressiv...
What is the current status of trial NCT00584935?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2006-01. Estimated completion is 2010-05.
What conditions does trial NCT00584935 study?
This clinical trial studies the following conditions: Ocular Cicatricial Pemphigoid.
What interventions are being tested in trial NCT00584935?
The interventions under investigation include: Rituximab (DRUG).
Who is sponsoring clinical trial NCT00584935?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00584935 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ocular Cicatricial Pemphigoid
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00584935's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia